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Abstract
Transgenic mouse T cells expressing the human CD3e chain bind the majority (29/36) of
monoclonal antibodies (mAbs) specific for human CD3. A proportion of these mAbs are also able
to recognize Isolated CD3e in a soluble, recomblnant form. Thus, CD3e can confer most CD3
epitopes on the TCR - CD3 complex, but many determinants may require assembly of the
complex for their formation. A number of mAbs did not recognize etransgenlc T cells and
probably need other CD3 subunlts for binding. CD3-speclfic mAbs from each of the three groups
defined here, as well as mAbs directed against the TCRa/3 heterodlmer, are all able to activate T
cells. Therefore mAb attachment at several different sites on the TCR - CD3 complex can give
rise to activation signals. This suggests that the cross-linking function of mltogenlc antibodies
may be their most significant property, rather than the perturbation of a particular 'functional
epltope'.
CD3 is a cluster of transmembrane proteins (termed y, 8, and
e) associated with antigen receptor on the T cell surface
(TCR-CD3 complex) (1,2). Most CD3-specific monoclonal
antibodies (mAbs) have mitogenic properties (3) and, largely as
a result of this finding, CD3 is thought to trigger T cell activation
subsequent to antigen recognition. However, the large number
of CD3-specific mAbs that have now been characterized can
show marked variation in their ability to elicit certain T cell
activation phenomena (4). Some of these effects may be
attributable to the avidity of the antibody for its target (5,6) or to
antibody isotype (reviewed in ref. 7), but in other cases it has
been suggested that the site of mAb binding may be important
(4), giving rise to the concept of 'functional' CD3 epitopes. It is
expected that a functional epitope corresponds to one or more
'physical' epitopes. Therefore, mapping antigenic determinants
on CD3 may define functionally important regions of the complex.
Although several studies implicate multiple epitopes on the
TCR-CD3 complex (8,9), little information on their localization
has so far been obtained. Standard cross-blocking techniques
on T cells have been largely umnformative since most
CD3-specific mAbs tested seem to block each other at least
partially (10-12). We have therefore taken two new approaches
to mapping mAb binding sites within the CD3 complex, using
(i) transgenic mice whose T cells express the human CD3e gene,
and (ii) recombinant soluble forms of CD37, -6, and -e.
Transgenic mice which carry the human CD3e gene were
found to express the transgene in thymocytes and peripheral T
cells, and to deliver the human CD3e protein to the cell surface
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as part of the mouse TCR - CD3 complex (A. Tunnacliffe et al.,
in preparation). When cultured spleen T cells from the transgenic
mice were stained with a panel of CD3-specific mAbs, it was
found that most (29/36) antibodies were positive, although of
varying intensity (Fig 1, Table 1) TCRa/3- or TCR7§-specific
mAbs were negative, as expected. All CD3-specific mAbs stained
human peripheral blood T cells equally well and were negative
on non-transgenic, httermate mouse T cells The 145-2C11 mAb,
specific for mouse CD3e (13), showed the converse staining
pattern (Fig. 1). These results demonstrate that the majority of
CD3 epitopes recognized by available CD3-specific mAbs are
conferred by the epsilon chain. To test whether some epitopes
rely for their formation on assembly of human CD3e into the
mouse TCR-CD3 complex, we assayed for binding of mAbs to
isolated CD3e in the form of a soluble recombinant molecule
Recombinant proteins have been generated which consist of
the extracellular domain of either human CD37, -6, or -e linked
to mouse C,. These soluble molecules—termed y-x, 5-x, and
e-x—are produced and secreted by myeloma-derived trans-
fectant clones, and are immunoprecptable by rat antisera raised
against purified CD3 subunits (14). Among the mAbs which
stained e-transgenic T cells, 18 were able to immunoprecipitate
surface-labelled, native CD3 (Figs 1 and 2a; summarized in
Table 1). These mAbs were tested against metabolically labelled
e-x, and as controls, y-x and b-x: a typical experiment is shown
in Fig. 2(b - d). Six mAbs, including the widely used UCHT1 and
Leu4 antibodies, bound e-x (Fig. 2d, Table 1) and therefore
recognize CD3e alone in the native TCR-CD3 complex.
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Table 1 . Summary of CD3 epitope mapping data
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Fig. 1. Staining of CD3e transgemc mouse, control littermate, and human
T cells by CD3-specific monoclonal antibodies Results are depicted as
curves of fluorescence distribution on a logarithmic scale The left
histogram in each pane) represents the binding of normal mouse serum
as background control Details of the construction of transgemc mice
carrying the human CD3e gene wfll be published elsewhere (A. Tunnacliffe
etal., in preparation). Mice (of the TG22 line) carrying multiple copies
(> 10) of the transgene were analysed here. Spleens were obtained from
either TG22 mice or control littermates that did not carry the transgene
and single cell suspensions were prepared from these organs Human
peripheral blood was from Kantonsspital (Basel) blood bank donors, and
mononuclear cells were isolated using Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden). Cells were maintained in 'complete medium',
consisting of RPMI 1640 medium supplemented with 2 mM glutamme,
10 mM HEPES, 50 mM 2-mercaptoethanol, and 10% heat-inactivated
foetal calf serum (GIBCO, Paisley, UK). To prepare T cell lines, cells
(2 x 10S/ml) were cultured in the pfesence of anti-CD3 mAb and 50 U/ml
recombinant interleukin 2 (rlL2) (Hoffmann-La Roche, Basel) for 4 days.
Then the cells were washed to remove unbound antibody and expanded
in complete medium containing 50 U/ml rll_2 by splitting the cultures (105
cells/ml) every second day. T cell lines used in the experiments reported
here were cultured for 12 days The procedure for immunofluorescence
surface staining of cells has been described (27). Ruorescan-conjugated
goat anti-mouse or anti-rat Ig (Southern Biotechnology) was used as a
second step reagent for human CD3-specific mAbs. 145-2C11 was
directly conjugated with fluorescein. Quanbtation of the surface
immuncfluorescence on 104 viable cells was performed with a FACScan
instrument (Becton-Dickinson, Mountain View, CA, USA) equipped with
a four decade logarithmic amplifier.
CD3
mAb name
Workshop no. Isotype
or reference
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PBL
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UCHT1
VIT3b
G19-4 1
SK7/Leu4
MEM-57
CD3-4B5
Group II
X35-3
VIT3
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(BW264/56)
CLB-T3/3
CRIS7
YTH12.5
F111-409
CLB-T3 4/2a
TR-66
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OKT3
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XIII-46
XIII-87
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T105-109
G2b
G2b
G1
G1
G1
G2a
a
+
+a
±
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+
+
+
+
+
+
+
+
±
+
_
_
_
_
_
-
—
_
_
_
_
—
NP
-
_
ND
-
-
-
-
-
_
ND
ND
NP
NP
NP
—
NP
-
—
NP
NP
ND
NP
NP
NP
NP
NP
NP
NP
NP
NP
ND
ND
ND
ND
The indicated TCR - CD3-specific mAb panel was assayed for surface
immunofluorescence in CD3e transgenic mice or human peripheral blood
T cells (PBL) (+ +, bright; +, dull; and - , negative staining) and immuno-
precipitation of recombinant soluble CD3e molecules (e*) (+, precipitates;
- , does not precipitate e-x but precipitates membrane CD3, NP, fails
to precipitate membrane CD3; ND, not tested).
aTCR76-speaftc antibodies stain brightly only a minor subset of PBL.
However, none of the 12 remaining mAbs, which stained
e-transgenic T cells, precipitated y-x, &-x, or t-x, despite their
ability to precipitate CD3 from T cells (e.g. Fig. 2, track 8; Table 1).
The data from the transgenic mouse and recombinant CD3
studies define a minimum of three groups of CD3-specific mAbs,
548 Most CD3 epitopes are conferred by the epsilon chain
a
1 2 3 4 5 6 7 8 91011121314
I CD3
4 6 7 8 1011 14 15
Y-K
6-K
e-K
Table 2. Effect of TCR-CD3-specific mAbs on the proliferation
of human T cells
mAb coated
Group I
UCHT1
Leu4
Group II
BMA030
TR-66
OKT3
T3/RW2-8C8
XIII-141
Group III
T3/2T8-2F4
BL-A8
M-T302
TCR
BMA032
WT31
Control
CD2 (OKT11)
CD5 (Leu-1)
PBS
[3H]thymidine uptake (c p m. x 10-3)
PBM PBT
47
68
31
44
70
61
39
24
30
53
67
32
0.5
1
07
35
46
ND
ND
58
50
34
20
ND
47
65
25
07
0 8
0.5
For proliferation assays, human peripheral blood mononuclear (PBM)
cells or T cells (PBT) purified using nylon wool columns (26) (2X105
cells/well) were cultured in flat-bottomed 96-well microtitre plates in
complete medium supplemented with antibodies in the indicated
combinations The mAbs (100 ng/well) were directly bound to the plastic
surface of the wells via a second step goat anti-mouse Ig antiserum
(Southern Biotechnology, Birmingham, AL, USA), as described elsewhere
(26). Wells were pulsed with 1 /iCi [3H]methyithymidme for the last 9 h
of a 4-day culture penod and the radioactivity incorporated into the cells
was estimated using a /9-counter ND, not tested
Fig. 2. Immunoprecipitation of native CD3 and recombmant CD3x
molecules by monoclonal CD3-specific antibodies, (a) lodinated CD3
precipitated from surface-labelled human T cells by monoclonal
antibodies. Lanes 1, BL-A8; 2, 12F6; 3, T10/B9; 4, MEM-57, 5, MEM-92;
6, OKT3D; 7, F111-409; 8, YTH12.5, 9, M-T301, 10, M-T302; 11,
CD3-4B5, 12, SMC2; 13, 'anti-T3', 14, UCHT1. (b-d) Metabolically
labelled y-x, 6-x, and ex respectively, precipitated by monoclonal
antibodies functional in Fig 2a, numbered identically. Lane 15 is a
polyclonal rabbit anti-mouse x serum, lodination of T cells (either Jurkat
or a CD3+ T cell clone) by the lactoperoxidase method and subsequent
immunoprecipitation were adapted from Kaufman et al. (28). Cells were
metabolically labelled for 4 h with 1 mCi [SSSJmethionine after 1 h
preincubation in methionine-free medium (Amimed, Basel, Switzerland).
Immune complexes were first resuspended in RIPA ( 1 % sodium
deoxycholate, 0 .1% sodium dodecyi sulphate, 150mM NaCI, 50 mM
Tns-HCI, pH 7.4) and washed in NET-NON (0 5% Nonidet P-40, 5 mM
EDTA, 150mM NaCI, 50 mM Tns-HCI, pH 8, 0 05% sodium azide),
followed by a PBS wash before electrophoresis. Antibody 12F6 gave
variable results- while in the expenment shown it failed to precipitate native
CD3, other expenments were positive
and therefore of corresponding epitopes (Table 1): group I, which
recognize CD3e, since they immunoprecipitate e-x and stain
e-transgenic T cells brightly; group II, which stain e-transgenic
T cells but do not recognize e-x; and group III, which do not bind
e-transgenic T cells or recombinant CD3 polypeptides but can
bind well to human T cells
Solid-phase mAbs from all 3 groups, as well as TCRa/3-specific
mAbs, were able to trigger human peripheral blood mononuclear
or purified T cells in a proliferation assay (Table 2). It is therefore
clear that a mitogenic stimulus can be delivered through a
number of different epitopes on the TCR-CD3 complex.
In summary, it has been demonstrated that most CD3 epitopes
(>80%) can be conferred by the human CD3e chain when
incorporated into a mouse TCR-CD3 complex. One-third of
these epitopes (defined by group I mAbs) could also be seen
on recombinant e-x, which unambiguously maps their position
within the native receptor. The group II mAbs, which do not bind
e-x but stain positively e-transgenic T cells, may be recognizing
conformational determinants which rely on association of CD3e
with other subunits in the complex for their formation. In this
regard, the variable intensity of staining of e-transgenic T cells
by group II mAbs may be explained by how well assembly-
dependent epitopes conferred by CD3e are formed in the
chimaeric mouse/human TCR-CD3 complex. A proportion
(7/36) of the antibody panel (group III) did not appear to recognize
epitopes conferred by CD3e, at least in association with mouse
TCR -CD3 subunits. These mAbs may require the presence of
other human polypeptides for binding.
Other workers have previously shown by Western blotting that
some of the group I mAbs identify CD3e (15). They also
demonstrated that these mAbs function in cytoplasmic immuno-
fluorescent staining experiments, whereas group II and (group
III) mAbs show no CD3-specific reactivity with either technique
(15). Such epitopes are apparently not found either on individual
CD3 chans or intracellular CD3 complexes. This further suggests
that many group II mAbs may be recognizing conformational
epitopes, dependent on the assembly of the whole TCR -CD3
complex. In the case of the F101.01 mAb, evidence has been
presented in support of this (16).
That the majority of CD3-specific mAbs recognize epitopes
involving CD3e (directly or indirectly) is probably a reflection of
the immunodominance of this subunit Strikingly, the differences
between the N-termmal sequences of human and mouse CD3e
seem to be clustered, a phenomenon not seen for the CD37 or
-6 chans, where sequence differences are more randomly
distributed (17). These patches of sequence disparity may
account for the strong mouse anti-human CD3e immune
response. Interestingly, two hamster anti-mouse CD3 mAbs also
recognize the CD3e chain (13,18). The bias of CD3-specrfic mAbs
to CD3e should temper the conclusions reached using such
mAbs in tests for the presence of the CD3 complex as a whole,
for example, in developmental studies. New mAbs are currently
being developed using soluble CD37 and -6 as immunogens
which will allow a more accurate assessment of the expression
and function of the individual CD3 components in a given cell
type.
Functional studies showed that CD3-specific mAbs in each
group, as well as TCRa/S-specific mAbs, can promote prolifer-
ation of human T cells and therefore that T cell activation by
receptor-binding mAbs can proceed through several, and
possibly multiple, epitopes. This raises doubts about the existence
of particular 'functional' epitopes on the CD3 complex,
perturbation of which is responsible for activation. Rather, it
suggests that the cross-linking function of mitogenic mAbs may
be their most significant property. Indeed, monovalent
CD3-specific mAbs do not seem to trigger T cells unless they
are cross-linked or bridged to a second cell (19). Furthermore,
despite several attempts to define functional epitopes on the
TCR-CD3 complex (4), we have been unable to correlate the
functional mAb groupings of other authors with those defined
here. This suggests that the properties of individual antibodies,
such as avidity and isotype, may have to be taken into account
in such studies.
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